New combo therapy shows promise for Hard-to-Treat cancers

NCT ID NCT04332653

First seen Feb 11, 2026 · Last updated May 14, 2026 · Updated 11 times

Summary

This study tested a combination of two drugs (NT-I7 and pembrolizumab) in 215 adults with advanced solid tumors that had come back or stopped responding to standard treatments. The goal was to find a safe dose and see if the combo could shrink tumors. The study also looked at immune cells in tumors to understand who might benefit most.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Mary Crowley Cancer Research

    Dallas, Texas, 75230, United States

  • Moffit Cancer Center

    Tampa, Florida, 33612, United States

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37211, United States

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.